Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002081
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Open-Label Program of Dideoxycytidine ddC to Be Used in Combination With Zidovudine AZT for Treatment of Advanced HIV Disease
Sponsor:
Hoffmann-La Roche
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Open-Label Program of Dideoxycytidine ddC to Be Used in Combination With Zidovudine AZT for Treatment of Advanced HIV Disease
Status:
COMPLETED
Status Verified Date:
1992-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide zalcitabine dideoxycytidine ddC for use with zidovudine AZT in patients with advanced HIV infection To observe serious toxicities in this population
Detailed Description:
Patients are treated with 1 of 2 doses of ddC administered orally PO in combination with AZT administered PO patients who are unable to tolerate this dose of AZT may receive a lower dose
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NV14147C | None | None | None |